Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC).

Metastatic Breast ◽

Abiraterone Acetate ◽

Phase 2 ◽

Phase 2 Study ◽

Estrogen Receptor Positive ◽

Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.520 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 520-520

Author(s):

Weimin Li ◽

Joyce O'Shaughnessy ◽

Deborah Sokol Ricci ◽

Thomas W. Griffin ◽

Thian San Kheoh ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Aromatase Inhibitor ◽

Metastatic Breast ◽

Abiraterone Acetate ◽

Estrogen Receptor Positive

Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer

Acta Oncologica ◽

10.1080/0284186x.2020.1851045 ◽

2020 ◽

pp. 1-8

Author(s):

Anne Sofie Brems-Eskildsen ◽

Søren Linnet ◽

Hella Danø ◽

Adam Luczak ◽

Peter Michael Vestlev ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Oral Capecitabine ◽

Phase 2 Study ◽

Metronomic Treatment ◽

Abstract S2-05: Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) withBRCA1orBRCA2mutations and metastatic breast cancer: A randomized, phase 2 study

10.1158/1538-7445.sabcs16-s2-05 ◽

2017 ◽

Cited By ~ 6

Author(s):

HS Han ◽

V Diéras ◽

ME Robson ◽

M Palácová ◽

PK Marcom ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study ◽

Abstract P5-14-05: The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study

10.1158/1538-7445.sabcs19-p5-14-05 ◽

2020 ◽

Author(s):

Elgene Lim ◽

Frances Boyle ◽

Meena Okera ◽

Sherene Loi ◽

Sema Sezgin Goksu ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Open Label ◽

Hormone Receptor Positive ◽

Phase 2 Study ◽

Previously Treated ◽

The Impact ◽

Abstract PD1-01: Open-label, randomized, phase 2 study of sapanisertib (TAK-228/MLN0128) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor-2-negative (HER2-) advanced or metastatic breast cancer (MBC) that previously progressed during or after aromatase inhibitor therapy (NCT02756364)

10.1158/1538-7445.sabcs20-pd1-01 ◽

2021 ◽

Author(s):

José Á García-Saenz ◽

Noelia Martínez Jáñez ◽

Miguel Martin ◽

Ainhara Lahuerta Martínez ◽

Santiago González-Santiago ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Open Label ◽

Aromatase Inhibitor Therapy ◽

Phase 2 Study ◽

Estrogen Receptor Positive ◽

Epidermal Growth ◽

A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial

Cancer ◽

10.1002/cncr.30141 ◽

2016 ◽

Vol 122 (19) ◽

pp. 2961-2970 ◽

Cited By ~ 5

Author(s):

Jan C. Drooger ◽

Harm van Tinteren ◽

Steffen M. de Groot ◽

Albert J. ten Tije ◽

Hiltje de Graaf ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Research ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Phase 2 Study ◽

Group Trial ◽

Abstract OT2-3-07: A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects withBRCA1orBRACA2mutation and metastatic breast cancer

10.1158/0008-5472.sabcs12-ot2-3-07 ◽

2012 ◽

Author(s):

SJ Isakoff ◽

S Pulhalla ◽

SP Shepherd ◽

N Falotico ◽

B Kaufman ◽

...

Keyword(s):

Breast Cancer ◽

Parp Inhibitor ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study ◽

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdv487 ◽

2016 ◽

Vol 27 (1) ◽

pp. 106-113 ◽

Cited By ~ 40

Author(s):

J. O'Shaughnessy ◽

M. Campone ◽

E. Brain ◽

P. Neven ◽

D. Hayes ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast ◽

Abiraterone Acetate ◽

Estrogen Receptor Positive

101P Significant Antitumor Activity in A Randomized Phase 2 Study Comparing 2 Schedules of Nktr-102 In Patients (Pts) with Metastatic Breast Cancer (Mbc)

Annals of Oncology ◽

10.1016/s0923-7534(19)65752-2 ◽

2012 ◽

Vol 23 ◽

pp. ii43 ◽

Cited By ~ 2

Author(s):

A. Awada ◽

S. Chan ◽

G.H.M. Jerusalem ◽

R.E. Coleman ◽

M.T. Huizing ◽

...

Keyword(s):

Breast Cancer ◽

Antitumor Activity ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study ◽

Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-15-2452 ◽

2016 ◽

Vol 22 (24) ◽

pp. 6002-6009 ◽

Cited By ~ 11

Author(s):

Weimin Li ◽

Joyce O'Shaughnessy ◽

Daniel Hayes ◽

Mario Campone ◽

Igor Bondarenko ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast ◽

Abiraterone Acetate ◽

Estrogen Receptor Positive